secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001664710-24-000038
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q1 net loss widens to $43.1M; cash $442.4M, runway into 2027
------------------------------------------------------------------

- Net loss of $43.1M in Q1 2024 vs $35.8M in Q1 2023, driven by higher R&D spending.
- R&D expenses $38.3M (up $7.2M YoY) reflecting pipeline advancement and manufacturing.
- Cash and equivalents $442.4M as of March 31, up from $331.1M at year-end.
- KER-050 Phase 3 MDS trial design discussed with FDA; update expected mid-2024.
- KER-012 TROPOS Phase 2 PAH trial update anticipated in Q2 2024; ATS poster in May.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/0001664710-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/kros-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer